ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

17 links0 made here, not in the record24 judgments2 judges (the rules as one: Rule based)3 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07566156Enfortumab Vedotin inCombination WithPembrolizumab vs.ConcurrentChemoradiotherapy (cCRT) inPeople With Muscle InvasiveBladder Cancer (EV-309)Astellas Pharma Global DevelopPhase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 30 · ClinicalTrials.gov record · Version of 2026-09-30Oct 19 · ClinicalTrials.gov record · Version of 2026-10-19Oct 28 · ClinicalTrials.gov record · Version of 2026-10-28Version of 2026-10-28CONDITIONSUrinary Bladder NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionUrologic NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedUrogenital NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedNeoplasms by SiteThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedNeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseFemale Urogenital DiseasesThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedUrogenital DiseasesThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseUrinary Bladder DiseasesThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedUrologic DiseasesThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedMale Urogenital DiseasesThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedCarcinoma, Transitional CellThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termDRUGSEnfortumab vedotinIntervention entry›Nov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCisplatinIntervention entry›Nov 10 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorFluorouracilIntervention entry›Nov 10 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorMitomycinEntry “Mitomycin C”, read by our name…›Nov 10 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorGemcitabineIntervention entry›Nov 10 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPembrolizumabIntervention entry›Nov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Enfortumab vedotin

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Enfortumab vedotin”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Sep 30The record itselfClinicalTrials.gov recordVersion of 2026-09-30Record change
Oct 19The record itselfClinicalTrials.gov recordVersion of 2026-10-19Record change
Oct 28The record itselfClinicalTrials.gov recordVersion of 2026-10-28Record change
Nov 10Enfortumab vedotinClaude Opus 5.5TestedCurrent
Nov 10CisplatinClaude Opus 5.5ComparatorCurrent
Nov 10FluorouracilClaude Opus 5.5ComparatorCurrent
Nov 10MitomycinClaude Opus 5.5ComparatorCurrent
Nov 10GemcitabineClaude Opus 5.5ComparatorCurrent
Nov 10PembrolizumabClaude Opus 5.5TestedCurrent
Nov 14Urinary Bladder NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Urologic NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Urogenital NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Neoplasms by SiteRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14NeoplasmsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Female Urogenital DiseasesRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Urogenital DiseasesRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Urinary Bladder DiseasesRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Urologic DiseasesRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Male Urogenital DiseasesRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Carcinoma, Transitional CellRule based · condition-kind ruleFinest filed termCurrent
Nov 18Enfortumab vedotinRule based · role ruleTestedAgrees
Nov 18CisplatinRule based · role ruleComparatorAgrees
Nov 18FluorouracilRule based · role ruleComparatorAgrees
Nov 18MitomycinRule based · role ruleComparatorAgrees
Nov 18GemcitabineRule based · role ruleComparatorAgrees
Nov 18PembrolizumabRule based · role ruleTestedAgrees
As of nowUrinary Bladder NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.